Switch studies in virologically suppressed patients

Switch to LPV/r monotherapy
HIV-NAT 077 Study: Switch double PI/r to LPV/r monotherapy
Original article : AIDS. 2011 Jan 28;25(3):315-23 – T Bunupuradah
Last update : 28/03/2014

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Simplifying second-line treatment from double-boosted PI therapy to LPV/r monotherapy allows for sustain virologic suppression in the majority of children after 48 weeks of follow-up


  • 50 HIV-1 infected Thaï children failing first line NRTIs + NNRTI, switched to double ritonavir-boosted PIs for 144 weeks (LPV/r + SQV = 90%) ; 40 children with virological suppression (HIV-1 RNA < 50 c/mL at least 3 months apart) switched to LPV/r 230/57.5 mg/m2 bid monotherapy
  • Female: 50%, Median age: 11.7 years
  • At W48
    • HIV-1 RNA < 50 c/mL: 72.5%
    • Still on LPV/r monotherapy, N = 31 (78%)
    • Returned to double boosted PIs due to failure, N = 9
    • No emergence of major protease resistance mutations

 

 

Back to Table of Contents

Copyright AEI 2017 | Links | Contact | Faculty and Disclosure | Terms of use aei